Hinge Health (HNGE) Q3 Earnings Preview: Tracking +45% Revenue Growth
Key Takeaways
- Hinge Health is set to report its third-quarter 2026 results (ended September 30, 2026) after the market close on Monday, November 2, 2026.
- Wall Street consensus calls for roughly $225 million in quarterly revenue and non-GAAP earnings of about $0.58 per share.
- The company guided third-quarter revenue to $223 million to $225 million, pointing to roughly 45% year-over-year growth at the midpoint.
- In its prior report, Hinge Health delivered $212.8 million in revenue (up 53% year over year) and $0.59 in non-GAAP earnings per share.
- Management lifted full-year 2026 revenue guidance to $856 million to $860 million, reflecting about 46% growth at the midpoint.
- The stock trades near its 52-week high, with analysts holding a consensus Buy rating and an average price target near $113.
Earnings Context and Why It Matters
Hinge Health operates as a digital healthcare provider specializing in musculoskeletal (MSK) care through software and AI-powered programs aimed at self-insured employers and health plans. It stands out in the digital-health space by combining rapid revenue expansion with a clear shift toward profitability. Heading into this report, the company has repeatedly met or exceeded its guidance while widening operating margins and producing solid free cash flow. For investors, the third-quarter update offers a key checkpoint on whether that momentum holds through the second half of 2026, particularly with the pending Cylinder Health acquisition and the push into new areas such as migraine treatment.
Earnings Expectations
Analysts project revenue of approximately $224.8 million for the third quarter of 2026, representing roughly 46% growth from the $154.2 million recorded a year earlier. The consensus non-GAAP earnings per share estimate stands near $0.58. Management’s guidance calls for revenue between $223 million and $225 million, which implies about 45% year-over-year growth at the midpoint, while the full-year 2026 outlook was raised to $856 million to $860 million.
The company brings a solid track record into this release. Second-quarter revenue reached $212.8 million, up 53% year over year and ahead of guidance, with non-GAAP operating income rising sharply and free cash flow hitting $99.6 million. Second-quarter non-GAAP EPS of $0.59 came in slightly below the roughly $0.62 consensus, showing that even a strong top-line result can miss on profitability metrics. I’m watching closely to see whether Hinge Health can again top its revenue guide and whether operating margins and cash flow continue to improve alongside the acquisition and multi-product expansion. I also checked this using Tickeron’s AI Screener to compare the stock with peers in the sector.
Market Reaction and Investor Sentiment
Sentiment ahead of the report remains broadly positive. Hinge Health shares have risen sharply since the May 2025 IPO and now trade near the upper end of their 52-week range, with a market capitalization of roughly $9 billion. Analyst actions have stayed constructive, with several firms lifting price targets and keeping Buy or Overweight ratings in the lead-up to the print.
This optimism also sets a high bar. Trading at a premium valuation, the market appears to have priced in continued strong execution, so a result that merely meets expectations may not satisfy investors. Key risks include the pace of revenue slowdown in the second half, the timing and integration of the Cylinder Health acquisition, and any pressure on margins or cash flow as the company scales newer product lines beyond its core musculoskeletal focus.
Forward Outlook and Key Factors to Monitor
Beyond the third quarter, the main question is whether Hinge Health can maintain high growth while protecting its expanding profitability. The guided path suggests a gradual slowdown from the 53% growth seen in the second quarter, which management has described as a natural comparison against a stronger second half of 2025. Investors will be looking for whether the company raises its full-year outlook again, as it has done several times over the past year.
A few elements stand out for attention. First, the integration of Cylinder Health, acquired for $105 million in cash as a virtual-first digestive-care provider, adds strategic breadth but is expected to add only modest revenue in 2026. Second, the launch of newer programs such as the migraine offering could influence the growth story into 2027. Third, operating leverage and free cash flow remain important proof points for the profitability narrative that has distinguished Hinge Health from less profitable digital-health peers. From what I see, valuation will stay a central theme given the premium multiple to sales, and the stock’s reaction will likely depend on whether management continues to deliver beats and upward revisions rather than simply matching expectations.
Using Tickeron Tools in My Research
In my own workflow, I find Tickeron’s AI Screener helpful for quickly scanning healthcare technology names and spotting patterns around earnings events like this one. It lets me apply filters for fundamentals, technical signals, and industry trends in one place, which saves time when preparing for reports like Hinge Health’s. I typically run a quick screen on comparable companies to see how the setup looks relative to the broader group before the print.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
HNGE's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for HNGE turned positive on October 01, 2026. Looking at past instances where HNGE's MACD turned positive, the stock continued to rise in 9 of 10 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 29, 2026. You may want to consider a long position or call options on HNGE as a result. In 19 of 24 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
Following a +7.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where HNGE advanced for three days, in 79 of 93 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The Aroon Indicator entered an Uptrend today. In 55 of 64 cases where HNGE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HNGE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.
HNGE broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 25 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. HNGE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: HNGE's P/B Ratio (26.135) is slightly higher than the industry average of (4.198). P/E Ratio (13.501) is within average values for comparable stocks, (13.596). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.012) among similar stocks. P/S Ratio (10.504) is also within normal values, averaging (6.065).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HNGE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement